Detalhe da pesquisa
1.
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Cancer
; 128(9): 1801-1811, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35195913
2.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
J Thorac Oncol
; 18(8): 1055-1069, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146754
3.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol
; 18(1): 79-92, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36049658
4.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol
; 17(2): 289-308, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648948
5.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Lung Cancer
; 150: 62-69, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070053